Effect of low‐dose cyclosporin a on systemic lupus erythematosus disease activity

Arthritis & Rheumatism

Volumn 37, Issue 4, 1994, Pages 551-558

  Tokuda, Michiaki ^a   Kurata, Noriyuki ^a   Mizoguchi, Akihito ^a   Inoh, Masayuki ^a   Seto, Kunio ^a   Kinashi, Makoto ^b   Takahara, Jiro ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b Kinashi Obayashi Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A;

ARTICLE; BONE MARROW TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFECT; HUMAN; HYPERTENSION; HYPERTRICHOSIS; NEPHROTOXICITY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 0028269624     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.1780370416     Document Type: Article

References (23)

1. Cyclosporine
2. Cyclosporin A: recent developments in the mechanism of action and clinical application
3. Clinical and immunological effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus
4. The 1982 revised criteria for the classification of systemic lupus erythematosus
5. Derivation of the SLEDAI: a disease activity index for lupus patients
6. Diagnostic significance of different urinary enzymes in patients suffering from chronic renal disease
7. 2‐microglobulin in the detection of cisplatin nephrotoxicity
8. Immune function in severe, active rheumatoid arthritis: a relationship between peripheral blood mononuclear cell proliferation to soluble antigens and mononuclear cell subset profiles
9. Effects of cyclosporin in severe systemic lupus erythematosus
10. Prednisolone and cyclosporin A exert differential inhibitory effects on T‐cell proliferation in vitro
11. Pathogenic anti‐DNA antibody‐inducing T helper cell lines from patients with active lupus nephritis: isolation of CD4‐8‐ T helper cell lines that express the γδT‐cell antigen receptor
12. Inhibition of in vitro anti‐DNA B‐cell responses by cyclosporine
13. Marked reduction of DNA antibody production and glomerulonephritis in thymulin (FTS‐Zn) or cyclosporin A treated (NZB x NZW) F1 mice
14. Prolongation of life in female (NZB x NZW) hybrid F1 mice by cyclosporin A
15. Successful treatment of autoimmunity in (NZB x NZW) F1 mice with cyclosporin and (Nva2)‐cyclosporin. I. Reduction of autoantibodies
16. Effects of cyclosporin A on autoimmune disease in MRL/1 and BXSB mice
17. Animal models utilized in the research of autoimmune disease control: experimental therapy of glomerulonephritis in NZB/W F1 mice
18. Interstitial pneumonitis in autoimmune MRL/lpr mice and its treatment with cyclosporine A
19. Increased class I and class II MHC products and mRNA in kidneys of MRL‐lpr/lpr mice during autoimmune nephritis and inhibition by cyclosporine
20. Development of autoimmunity in MRL/lpr mice and the effects of drugs on this murine disease
21. Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo